HR 5982
116th Congress
House
Health
Administrative law and regulatory procedures
Asia
China
Congressional oversight
Drug safety, medical device, and laboratory regulation
Government studies and investigations
Health care costs and insurance
Health information and medical records
Health technology, devices, supplies
Manufacturing
Prescription drugs
Public contracts and procurement
Trade restrictions
Safe Medicine Act
Introduced: February 26, 2020
See on congress.gov
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 26, 2020
Referred to the House Committee on Energy and Commerce.
Feb 26, 2020
Introduced in House
Plain-English summary
Safe Medicine Act
This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination.
The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.
What's happening now
Referred to the House Committee on Energy and Commerce.
Committees of jurisdiction
1
Cosponsors
1